Literature DB >> 22729569

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.

Jordan M Winter1, Charles J Yeo, Jonathan R Brody.   

Abstract

Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22729569     DOI： 10.1002/jso.23192

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  103 in total

1.  Pancreatic Cancer: a Challenge to Cure.

Authors:  M Tewari
Journal:  Indian J Surg       Date:  2015-10-19       Impact factor: 0.656

2.  Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.

Authors:  Christopher Y Kang; Jonathan Wang; Dierdre Axell-House; Pranay Soni; Mon-Li Chu; Galina Chipitsyna; Konrad Sarosiek; Jocelyn Sendecki; Terry Hyslop; Mazhar Al-Zoubi; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

3.  Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.

Authors:  Neveen Abd El Moneim Hussein; Zenat A El Kholy; Medhat M Anwar; Mohamed A Ahmad; Shaymaa M Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-15       Impact factor: 4.553

4.  Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation.

Authors:  Qing-Cai Meng; Hong-Cheng Wang; Zi-Liang Song; Ze-Zhi Shan; Zhou Yuan; Qi Zheng; Xin-Yu Huang
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 5.  Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.

Authors:  Helena Verdaguer; Tamara Saurí; Teresa Macarulla
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 6.  Gold Nanoparticles for In Vitro Diagnostics.

Authors:  Wen Zhou; Xia Gao; Dingbin Liu; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2015-06-26       Impact factor: 60.622

7.  Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.

Authors:  Jiangning Gu; Di Wang; Ya Huang; Yi Lu; Chenghong Peng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

8.  Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.

Authors:  Ze-Kun Zhao; Wen-Guang Wu; Lei Chen; Ping Dong; Jun Gu; Jia-Sheng Mu; Jia-Hua Yang; Ying-Bin Liu
Journal:  Tumour Biol       Date:  2013-01-26

Review 9.  Intensity of follow-up after pancreatic cancer resection.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Ann Surg Oncol       Date:  2013-10-04       Impact factor: 5.344

10.  CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Ji-Cong Gui; Wei-Li Yan; Xing-Dang Liu
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.